Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Aprea Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DOYLESTOWN, PA., OCT. 24, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIES WHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY PROVIDED AN UPDATE ON THE ONGOING PHASE 1 ACESOT-1051 (A MULTI-CENTER EVALUATION OF WEE1 INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS, APR-1051) STUDY. THE LATEST RESULTS SHOW THAT, AT THE 100 MG APR-1051 DOSE LEVEL, 3 OUT OF 4 PATIENTS ACHIEVED STABLE DISEASE, AS MEASURED USING RECIST V1.1 CRITERIA.

APREA THERAPEUTICS PROVIDES CLINICAL UPDATE FROM ACESOT-1051 TRIAL SHOWING EARLY SIGNALS OF ACTIVITY FOR WEE1 KINASE INHIBITOR APR-1051

ATRN-119 (ATR INHIBITOR): RP2D OF 1,100 MG ONCE DAILY IDENTIFIED IN ONGOING ABOYA-119 DOSE-ESCALATION STUDY FURTHER ATRN-119 MONOTHERAPY ENROLLMENT PAUSED WITH STRATEGIC FOCUS ON HIGH-VALUE COMBINATION COMPANY IS PRIORITIZING ITS LEAD PROGRAM, WEE1 KINASE INHIBITOR APR-1051 DOYLESTOWN, PA., OCT. 15, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIESWHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY ANNOUNCED THAT IT HAS DETERMINED THE RECOMMENDED PHASE 2 DOSE (RP2D) OF 1,100 MG ONCE DAILY FOR ATRN-119, ITS ORAL ATR INHIBITOR IN THE MONOTHERAPY ARM OF THE ONGOING ABOYA-119 PHASE 1/2A DOSE-ESCALATION STUDY, IN PATIENTS WITH ADVANCED SOLID TUMORS.

APREA THERAPEUTICS ESTABLISHES RECOMMENDED PHASE 2 DOSE (RP2D) FOR ATRN-119, CONSIDERING COMBINATION THERAPIES

DOYLESTOWN, PA., OCT. 14, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIES WHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY ANNOUNCED THAT TWO ABSTRACTS ON ITS CLINICAL PROGRAMS, APR-1051 AMD ATRN-119, HAVE BEEN ACCEPTED FOR POSTER PRESENTATION AT THE EORTC-NCI-AACR INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS, TAKING PLACE OCTOBER 22 - 26, 2025 AT THE HYNES CONVENTION CENTER IN BOSTON, MASSACHUSETTS.

APREA THERAPEUTICS ANNOUNCES PRESENTATIONS AT EORTC-NCI-AACR INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

DOYLESTOWN, PA., AUG. 28, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIESWHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE, TO TAKE PLACE SEPTEMBER 8-10, 2025, IN NEW YORK.

APREA THERAPEUTICS TO PRESENT AT H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

EARLY EVIDENCE OF DISEASE CONTROL WAS OBSERVED IN THE ONGOING PHASE 1 ACESOT-1051 TRIAL, WITH THREE PATIENTS ACHIEVING STABLE DISEASE IN THE 70 MG AND 100 MG COHORTS TREATED WITH THEWEE1 INHIBITOR, APR-1051

APREA THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CLINICAL UPDATE

PRECLINICAL DATA DEMONSTRATE POTENT SINGLE-AGENT AND COMBINATION EFFECTS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) MODELS, INCLUDING SYNERGY WITH ANTIPD-1 THERAPY

APREA REPORTS ANTI-PROLIFERATIVE RESULTS AND PROMISING EARLY-STAGE CLINICAL DATA FOR NEXT-GENERATION WEE1 INHIBITOR, APR-1051, IN HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IN COLLABORATION WITH MD ANDERSON CANCER CENTER

ATRN-119, OUR ATR INHIBITOR, EXHIBITS EARLY EVIDENCE OF SINGLE AGENT, ANTI-TUMOR ACTIVITY AND IS PROGRESSING TOWARD THE RECOMMENDED PHASE 2 DOSE (RP2D) IN THE ONGOING ABOYA-119 CLINICAL TRIAL

APREA THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CLINICAL UPDATE

ACESOT-1051 TRIAL EXPANDED TO INCLUDE HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) PATIENTS, TARGETING POPULATIONS MOST LIKELY TO BENEFIT FOR WEEI INHIBITION ACESOT-1051 TRIAL EXPANDED TO INCLUDE HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) PATIENTS, TARGETING POPULATIONS MOST LIKELY TO BENEFIT FOR WEEI INHIBITION

APREA THERAPEUTICS ANNOUNCES DOSING OF PATIENT WITH HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IN ONGOING ACESOT-1051 TRIAL

ACESOT-1051 TRIAL EVALUATING WEE1 KINASE INHIBITOR APR-1051 NOW ENROLLING PATIENTS IN COHORT 5; OPEN LABEL SAFETY AND EFFICACY DATA EXPECTED H2 2025 TWICE DAILY (BID) DOSING REGIMEN IN ONGOING ABOYA-119 TRIAL EXPECTED TO MAXIMIZE CLINICAL BENEFIT OF ATR INHIBITOR ATRN-119; PLAN TO COMPLETE DOSE ESCALATION H2 2025 $22.8 MILLION IN CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2024 DOYLESTOWN, PA., MARCH 25, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIESWHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024, AND PROVIDED A BUSINESS UPDATE.

APREA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

DOYLESTOWN, PA., MARCH 11, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIESWHILE MINIMIZING DAMAGE TO HEALTHY CELLS, ANNOUNCED TODAY THAT IT HAS ENTERED INTO A MATERIAL TRANSFER AGREEMENT (MTA) WITH MD ANDERSON CANCER CENTER. UNDER THE AGREEMENT, APREA WILL SUPPLY ITS PROPRIETARY WEE1 KINASE INHIBITOR, APR-1051, TO SUPPORT PRECLINICAL RESEARCH AIMED AT EXPLORING ITS POTENTIAL IN TREATING HPV+ AND HPV- HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) EXPRESSING GENOMIC MARKERS OF REPLICATION STRESS.

APREA THERAPEUTICS ANNOUNCES AGREEMENT WITH MD ANDERSON CANCER CENTER TO EXPLORE APR-1051 AS A POTENTIAL TREATMENT FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)

Aprea Therapeutics, Inc.

APRE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Aprea Therapeutics, Inc.

APRE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

APRE